Mirdametinib Offers Second Targeted Therapy Option Against Rare Genetic Disorder
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food...
Progress Against Cancer
The FDA has approved a new MEK inhibitor for certain patients with symptomatic neurofibromatosis type 1. The U.S. Food...
The FDA has approved fam-trastuzumab deruxtecan-nxki for certain HER2-low or HER2-ultralow breast cancers. The U.S. Food and Drug Administration...
The FDA approved treosulfan and fludarabin for patients with hematologic disorders prior to stem cell transplantation. The U.S....
The FDA has issued its first approval for datopotamab deruxtecan-dlnk, a targeted therapy, for certain types of breast cancer. ...
The FDA approved sotorasib and panitumumab for metastatic colorectal cancer with the KRAS G12C mutation. The U.S. Food and...
Acalabrutinib was granted traditional approval as a monotherapy for previously treated MCL and as part of a combination for...
The FDA approved nivolumab and hyaluronidase-nvhy as an injectable therapy for multiple tumor types. The U.S. Food and Drug...
The FDA approved the kinase inhibitors encorafenib and cetuximab plus chemotherapy for the treatment of certain colorectal cancers. The...
The FDA approved the mesenchymal stromal cell therapy remestemcel-L-rknd for some pediatric patients as young as 2 months. ...
The FDA approved ensartinib for certain patients with locally advanced or metastatic non-small cell lung cancer. The U.S. Food...